---
document_datetime: 2023-09-21 22:02:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_en.pdf
document_name: akeega-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7637382
conversion_datetime: 2025-12-24 08:17:46.565666
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA(EU) number    | (Invented) name   | Strength       | Pharmaceutical form   | Route of administration   | Immediate Packaging       | Pack size   |
|------------------|-------------------|----------------|-----------------------|---------------------------|---------------------------|-------------|
| EU/1/23/1722/001 | Akeega            | 50 mg / 500 mg | Film-coated tablet    | Oral use                  | blister (PVdC/PE/PVC/alu) | 56 tablets  |
| EU/1/23/1722/002 | Akeega            | 100mg / 500 mg | Film-coated tablet    | Oral use                  | blister (PVdC/PE/PVC/alu) | 56 tablets  |